WHO ICTRP trial
A First-in-Human Safety Trial of MTX-474
ACTRN12624000725561 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12624000725561 |
|---|---|
| Public title | A First-in-Human Safety Trial of MTX-474 |
| Scientific title | A Phase 1 Randomized, Double-Blind, Dose- Escalating Study to assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults |
| Primary sponsor | Mediar Therapeutics |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Systemic Sclerosis; Systemic Sclerosis;Inflammatory and Immune System - Connective tissue diseases |
| Interventions | This is a randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered by a… |
| Registration date | Jun 13, 2024 |
| Target size | 80 |
| Secondary IDs | MTX-474-S101 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: